Strategic Funding TISSIUM has secured substantial financing including a €60 million package with a €30 million Series D2 and a €30 million facility from the EIB, signaling strong investor confidence and potential for sustained R&D collaboration, co-development deals, and large-scale manufacturing partnerships.

Nerve Repair Focus Recent competitive positioning against BioCircuit Technologies in the nerve repair space, along with ongoing development of atraumatic, sutureless solutions like COAPTIUM CONNECT, indicates a clear opportunity to map and approach neurovascular and peripheral nerve repair stakeholders, hospitals, and trauma centers.

Platform Expansion Active exploration of the TISSIUM platform across additional applications, including nerve repair, suggests sales opportunities to diversify into multidisciplinary surgical fields, leveraging existing polymers and delivery technologies to partner with orthopedics, plastics, and reconstructive specialties.

Clinical Leadership New senior clinical leadership hires, such as the Vice President of Clinical Affairs, point to a heightened emphasis on clinical evidence generation and KOL engagement, creating openings for clinical study collaborations, trials, and hospital-based adoption programs.

Global Collaboration Co-development platform with medtech partners and presence across Paris, Cambridge, and regulatory-aligned Europe funding create entry points for joint ventures, licensing discussions, and contract manufacturing opportunities to scale production and accelerate market entry.